glycine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1319 56-40-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • glycine
  • 2-aminoacetic acid
  • aminoacetic acid
A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.
  • Molecular weight: 75.07
  • Formula: C2H5NO2
  • CLOGP: -3.21
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 63.32
  • ALOGS: 0.87
  • ROTB: 1

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT1,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK2,PDK4,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 53
kinase-selectivity-class ACVR2B,AXL,BMX,BRAF,CDK9,DDR1,DYRK1B,EPHB4,GRK2,MAP2K6,MAPK7,PIK3CB,PIK3CD,PIK3CG,PRKDC,STK33,TEK,TGFBR1 18
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
May 25, 1976 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Status epilepticus 83.30 69.11 18 303 18856 90609270
Foetal growth restriction 77.08 69.11 15 306 9365 90618761
Stevens-Johnson syndrome 75.37 69.11 18 303 29358 90598768

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vasoplegia syndrome 44.65 36.56 9 369 2646 42618311
Compartment syndrome 42.72 36.56 9 369 3280 42617677
Coma scale abnormal 39.78 36.56 9 369 4556 42616401
Pulse absent 36.86 36.56 9 369 6318 42614639

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Stevens-Johnson syndrome 59.52 40.64 18 571 46883 110541827
Status epilepticus 57.27 40.64 16 573 31555 110557155
Skin laceration 47.32 40.64 14 575 33739 110554971
Sopor 46.22 40.64 14 575 36532 110552178
Vasoplegia syndrome 42.75 40.64 9 580 5430 110583280
Compartment syndrome 42.00 40.64 9 580 5901 110582809

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B05CX03 BLOOD AND BLOOD FORMING ORGANS
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
IRRIGATING SOLUTIONS
Other irrigating solutions
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018684 Glycine Agents
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:25512 neurotransmitter
CHEBI has role CHEBI:27027 micronutrient
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:50733 nutraceutical
CHEBI has role CHEBI:62868 hepatoprotective agent
CHEBI has role CHEBI:64570 EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor
CHEBI has role CHEBI:64571 NMDA receptor agonist
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:64952 anti-HSV agent
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:78675 fundamental metabolite

Related Drugs by ATC class:

B05CX Other irrigating solutions 3 drugs
glucosemannitolsorbitol

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Cough indication 49727002
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Rhinitis indication 70076002 DOID:4483
Common cold indication 82272006 DOID:10459
Classical phenylketonuria contraindication 7573000
Poisoning by digitalis glycoside contraindication 12876009
Constipation contraindication 14760008 DOID:2089
Hyperphosphatemia contraindication 20165001 DOID:0050459
Hypervitaminosis D contraindication 27712000 DOID:9971
Sarcoidosis contraindication 31541009 DOID:11335
Dehydration contraindication 34095006
End stage renal disease contraindication 46177005 DOID:784
Humoral hypercalcemia of malignancy contraindication 47709007
Heart disease contraindication 56265001 DOID:114
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Ventricular fibrillation contraindication 71908006
Hypercalciuria contraindication 71938000
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Osteolysis contraindication 203522001
Arteriosclerosis obliterans contraindication 361133006 DOID:5160




🐶 Veterinary Drug Use

SpeciesUseRelation
Cattle Dehydration associated with diarrhea Indication
Cattle Early treatment of scouring Indication
Cattle Treatment following intravenous fluid therapy Indication

🐶 Veterinary products

ProductApplicantIngredients
Re-Sorb, Vytrate Zoetis Inc. 6

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.21 acidic
pKa2 9.94 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium- and chloride-dependent glycine transporter 1 Transporter IC50 4.50 CHEMBL
Olfactory receptor 51E2 GPCR EC50 7.24 CHEMBL
Glutamate receptor ionotropic, NMDA 1 Ion channel IC50 6.60 CHEMBL
Glutamate NMDA receptor Ion channel Ki 6.77 CHEMBL

External reference:

IDSource
TE7660XO1C UNII
4017980 VUID
N0000146327 NUI
D00011 KEGG_DRUG
4017980 VANDF
C0017890 UMLSCUI
CHEBI:15428 CHEBI
GLY PDB_CHEM_ID
CHEMBL773 ChEMBL_ID
750 PUBCHEM_CID
DB00145 DRUGBANK_ID
D005998 MESH_DESCRIPTOR_UI
630 INN_ID
727 IUPHAR_LIGAND_ID
4919 RXNORM
4793 MMSL
603 MMSL
NOCODE MMSL
d06640 MMSL
000929 NDDF
003191 NDDF
15331006 SNOMEDCT_US
346464005 SNOMEDCT_US
TE7660XO1C INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.36 g INTRAVENOUS NDA 23 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 1.04 g INTRAVENOUS ANDA 20 sections
Glycine HUMAN PRESCRIPTION DRUG LABEL 1 0264-7390 IRRIGANT 1.50 g IRRIGATION NDA 13 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 824 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION 824 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 515 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 824 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 618 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0202 INJECTION 824 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0206 INJECTION 824 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0210 INJECTION 824 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0214 INJECTION 824 mg INTRAVENOUS NDA 20 sections
Glycine HUMAN PRESCRIPTION DRUG LABEL 1 0338-0289 SOLUTION 1.50 g IRRIGATION NDA 16 sections
ProSol HUMAN PRESCRIPTION DRUG LABEL 17 0338-0499 INJECTION, SOLUTION 2.06 g INTRAVENOUS NDA 21 sections
Clinisol HUMAN PRESCRIPTION DRUG LABEL 17 0338-0502 INJECTION, SOLUTION 1.04 g INTRAVENOUS ANDA 18 sections
Travasol HUMAN PRESCRIPTION DRUG LABEL 15 0338-0644 INJECTION 1.03 g INTRAVENOUS NDA 20 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1089 INJECTION 438 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1091 INJECTION 438 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1099 INJECTION 515 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1101 INJECTION 515 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1113 INJECTION 438 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1115 INJECTION 438 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1123 INJECTION 515 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1125 INJECTION 515 mg INTRAVENOUS NDA 20 sections
Premasol - sulfite-free (Amino Acid) HUMAN PRESCRIPTION DRUG LABEL 19 0338-1130 INJECTION, SOLUTION 0.36 g INTRAVENOUS ANDA 15 sections
Premasol - sulfite-free (Amino Acid) HUMAN PRESCRIPTION DRUG LABEL 19 0338-1131 INJECTION, SOLUTION 0.22 g INTRAVENOUS ANDA 15 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1133 INJECTION 438 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1134 INJECTION 438 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1137 INJECTION 515 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1138 INJECTION 515 mg INTRAVENOUS NDA 21 sections